Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Programmed cell death in lung cancer: mechanisms, immune responses, and therapeutics

Liu, Yang, Chen, Qingxin, Xu, Jiayu and Chi, Hao 2026. Programmed cell death in lung cancer: mechanisms, immune responses, and therapeutics. Apoptosis 31 , 128. 10.1007/s10495-026-02298-y

[thumbnail of Programmed Cell Death in Lung Cancer Mechanisms Immune Responses and Therapeutic.pdf]
Preview
PDF - Accepted Post-Print Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Lung cancer remains the leading cause of cancer‐related mortality worldwide, with an estimated 2.2 million new cases and 1.8 million deaths in 2020. Despite improvements achieved through cytotoxic chemotherapy and immune checkpoint blockade, survival outcomes for many patients remain unsatisfactory, largely due to tumour immune-evasion and resistance to immunotherapy. In this context, programmed cell death (PCD) pathways—especially apoptosis, pyroptosis, ferroptosis and necroptosis—play central roles in shaping tumour cell fate, modulating the tumour immune microenvironment, and influencing therapeutic response. Apoptosis typically proceeds via caspase-mediated dismantling and is often immune-tolerogenic, whereas pyroptosis, ferroptosis and necroptosis provoke danger signals, inflammation and potent dendritic cell and T-cell activation, thus serving as immunogenic cell death modalities. Reciprocal crosstalk between these PCD types and the immune system determines whether lung tumours remain “cold” (immune‐excluded) or become “hot” (immune‐inflamed). Importantly, targeting these classical PCD mechanisms—either alone or in combination with immunotherapy—emerges as a promising strategy to overcome immune resistance in lung cancer by converting non-responsive tumours into immune-sensitive states. This review synthesises mechanistic insights into how apoptosis, pyroptosis, ferroptosis and necroptosis regulate antitumour immunity in lung cancer and outlines therapeutic opportunities for targeting PCD to enhance immunotherapy efficacy and overcome immune-resistant phenotypes.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Schools > Computer Science & Informatics
Additional Information: RRS policy applied
Publisher: Springer Verlag (Germany)
ISSN: 1360-8185
Date of First Compliant Deposit: 28 April 2026
Date of Acceptance: 1 February 2026
Last Modified: 05 Aug 2026 12:30
URI: https://orca.cardiff.ac.uk/id/eprint/186647

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics